Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quince Oxymel vs Propranolol for Migraine Prevention
NCT02179775Unknown
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of quince oxymel in migraine (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: frequency of headache attacks at 4 weeks, duration of headache attacks at 4 weeks and 1 more. Status: unknown.
02
Drugs
quince oxymel
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02179775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179775.